11 results about "Lipid moiety" patented technology

The invention relates to an ionizable cationic lipid mediated lung targeting nucleic acid delivery system and application. Specifically, the present invention provides a lipid nanoparticle, the lipid portion of which comprises an ionizable cationic lipid, a phospholipid, and a polyethylene glycol lipid, in which the ionizable cationic lipid comprises Compound 1, and in which the content of Compound 1 is 80 mol% or more based on the total amount of lipid in the lipid nanoparticle. According to the lipid nanoparticles, the lung targeting efficiency is remarkably improved, and the preparation design process is simplified.

The present disclosure provides a Lipid-Phosphocholine-Carboxylic Acid Agent being a compound comprising one or more groups, wherein each group is independently selected from Lipid Moiety (LM), Phosphocholine Moiety (PCM), Carboxylic Acid Moiety, Amide Moiety, and Attachment Moiety (AM), and wherein each group is covalently attached, directly or indirectly, to a multivalent linker (i.e., Composition Linker Moiety (CLM)), or pharmaceutically acceptable salts thereof, and related conjugates. The present disclosure also relates to uses of the Lipid-Phosphocholine-Carboxylic Acid Agents and conjugates, e.g., in delivering nucleic acid and / or treating or preventing diseases.

The present disclosure provides a Lipid-Phosphocholine-Carboxylic Acid Agent being a compound comprising one or more groups, wherein each group is independently selected from Lipid Moiety (LM), Phosphocholine Moiety (PCM), Carboxylic Acid Moiety, Amide Moiety, and Attachment Moiety (AM), and wherein each group is covalently attached, directly or indirectly, to a multivalent linker (i.e., Composition Linker Moiety (CLM)), or pharmaceutically acceptable salts thereof, and related conjugates. The present disclosure also relates to uses of the Lipid-Phosphocholine-Carboxylic Acid Agents and conjugates, e.g., in delivering nucleic acid and / or treating or preventing diseases.

To provide formulated and / or co-formulated liposomal compositions containing TFG β antagonist prodrugs useful in the treatment of cancer, and methods thereof.SOLUTION: Disclosed herein are formulated and / or co-formulated liposomes (LNPs) and solid lipid nanoparticles (SLNPs) comprising TB prodrugs, and methods of making said LNPs and SLNPs. TB pro-drug compositions comprise a drug moiety, a lipidic moiety, and a linking unit, and inhibit ALK5. TB prodrugs can be formulated and / or co-formulated into liposomes or solid lipid nanoparticles to provide a method of treating cancer, immunological disorders, and other diseases by utilizing a targeted drug delivery vehicle.SELECTED DRAWING: None

Disclosed herein are formulated and / or co-formulated liposomes, lipid nanoparticles (LNPs), and solid lipid nanoparticles (SLNPs) comprising a TB prodrug, as well as methods of making the LNPs and the SLNPs. The TB prodrug composition includes a drug moiety, a lipid moiety, and a linking unit that inhibits ALK5. The TB prodrugs may be formulated and / or co-formulated into nanocarriers to provide methods of treating cancer, immune disorders, and other diseases by utilizing targeted drug delivery vehicles.

The invention relates to a process for the preparation of a composition comprising an oligosaccharide or a polysaccharide encapsulated in lipid nanoparticles, the process comprising the following steps: preparing a first solution of a lipid portion comprising a phospholipid, a neutral lipid, and a lipid sterol; preparing a second solution comprising a poly- or oligosaccharide; preparing a third solution containing a buffer; mixing the first and second solutions using a microfluidic system to obtain lipid nanoparticles encapsulating the oligosaccharide or the polysaccharide; combining the third solution with the first and second solutions. The invention also relates to a composition comprising lipid nanoparticles obtainable by the above-defined process, said composition comprising a lipid portion comprising a phospholipid, a neutral lipid compound in which a lipid chain is bound to a glycol group, and a lipid sterol; a buffer; and an oligosaccharide or polysaccharide.

The present application relates to ionizable cationic lipid-mediated pulmonary targeting nucleic acid delivery system and application. Specifically, the present application provides a kind of lipid nanoparticles, the lipid part of the lipid nanoparticles includes ionizable cationic lipid, phospholipid and polyethylene glycol lipid, wherein ionizable cationic lipid includes compound 1, and wherein the content of compound 1 is 80 mol% or more based on the total amount of lipid in the lipid nanoparticle. The lipid nanoparticle significantly improves the lung targeting efficiency and simplifies the formulation design process.

Described are vaccine compositions, methods of manufacture thereof, and methods of treating or preventing certain bacterial infections in humans and other mammals. For example, described are compositions comprising bacterial cell extracts that have undergone pretreatment such that lipid moieties have been cleaved from bacterial lipoproteins, thereby forming a vaccine composition that can stimulate a desired mammalian immune response while avoiding unwanted negative effects.

The invention pertains to a genetically modified Neisseria bacterium comprising a lipopolysaccharide (LPS) having a lipid A moiety and a modified oligosaccharide core, wherein the modified oligosaccharide core comprises a first oligosaccharide chain coupled to heptose 1 and a second oligosaccharide chain coupled to heptose 2, wherein the first and second oligosaccharide chain comprise a lactose directly coupled to respectively heptose 1 and 2, thereby forming a Neisseria gonorrhoeae 2C7 epitope. The modified bacterium may express a further non-native N. gonorrhoeae antigen, such as MetQ, AniA or NspA. The modified Neisseria bacterium is not Neisseria gonorrhoeae. The bacterium is preferably Neisseria meningitidis, Neisseria lactamica or Neisseria cinerea. The invention further pertains to LPS and OMVs obtained from the genetically modified bacterium, as well as methods for producing said modified bacterium.

The present invention relates to a lipopeptide building block consisting of(i) a peptide moiety comprising a coiled coil peptide chain segment, wherein said coiled coil peptide chain segment comprises 3 to 8 repeat units, and wherein said repeat unit consists of the sequence IEKKIE-X0 (SEQ ID NO:58), wherein X0 represents an amino acid, and wherein preferably said repeat unit consists of the sequence selected from IEKKIEG (SEQ ID NO:59), IEKKIEA (SEQ ID NO:12) or IEKKIES (SEQ ID NO:13), and wherein further preferably said repeat unit consists of the sequence IEKKIES (SEQ ID NO:13);(ii) a lipid moiety comprising, preferably consisting of, the formula LM-Iwherein R1 and R2 are independently C11-15alkyl, wherein preferably R1 and R2 are independently —C11H23, —C13H27 or —C15H31, and wherein further preferably R1 and R2 are —C15H31; and wherein R3 is hydrogen or —C(O)C11-15alkyl, and wherein preferably R3 is H or —C(O)C15H31;and wherein said lipid moiety is linked to said peptide moiety, wherein the wavy line in formula LM-I indicates the linkage site to said peptide moiety, and wherein preferably said lipid moiety is linked to the N-terminus of said peptide moiety, as well as conjugates comprising said lipopeptide building blocks to which antigens are coupled, bundles of such conjugates, synthetic virus-like particles (SVLPs) comprising at least one bundle of conjugates and pharmaceutical compositions comprising the same. The present invention further relates to said conjugates, bundles of conjugates, said SVLPs and said pharmaceutical compositions for use as a medicament, as vaccines and for use in methods of preventing or treating a disease, preferably selected from infectious diseases, allergies and cancer, and generally to efficiently induce antigen specific immune responses.

To provide subcutaneous telomerase inhibitor compositions and methods for using the same.SOLUTION: Aspects of the present disclosure include telomerase inhibitor compositions formulated for subcutaneous administration. Compositions according to certain embodiments comprise a hyaluronidase enzyme and a telomerase inhibitor comprising an oligonucleotide and a lipid moiety conjugated to the 5' and / or 3' end of the oligonucleotide. Methods for subcutaneously administering telomerase inhibitor compositions, such as in the treatment of tumors, are also described. Kits with or without hypodermic syringes are also provided.SELECTED DRAWING: None